Recent News

• 02.26.2025 - Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis
• 02.19.2025 - Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal
• 01.16.2025 - United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer
• 01.15.2025 - Biomerica Reports Second Quarter Fiscal 2025 Financial Results
• 01.15.2025 - Biomerica Reports Second Quarter Fiscal 2025 Financial Results
• 11.21.2024 - Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
• 11.07.2024 - Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements

Recent Filings

• 02.11.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 12.20.2024 - S-8 Securities to be offered to employees in employee benefit plans
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2024 - 8-K Current report
• 12.17.2024 - 4 Statement of changes in beneficial ownership of securities